ThetaPal ThetaPal

Manufacturing / Pharmaceutical Preparations

NOVO NORDISK A S

NVO

$43.36

+$0.05 (+0.12%)

Price as of Sep 18, 2026 22:09 UTC

200 B

Market Cap (Large Cap)

17%

IV Rank

36.5%

Implied Volatility

Nov 05

Next Earnings

Technical Signals as of Sep 16
Bearish
0 of 7

Trend

  • Above 20-day average $44.96
  • Above 50-day average $45.95
  • Above 200-day average $47.63 · -12.4%
  • Moving averages stacked Not aligned

Momentum

  • Golden cross (50/200)
  • Momentum cross (20/50) Down · 12d ago

Volume

  • Below-average volume 1.1x avg

Price & Trend

Daily candles with EMA 20, SMA 50. Drag to zoom.

Options Activity & Greeks

Implied volatility, flow, and dealer positioning from the options market.

Put/Call Ratio

0.63

Bullish skew

Implied Volatility

36.5%

0% percentile

IV vs Realized

Options rich

30d HV 31.3%

Options Heat Map

Delta-risk grid for NVO options across strikes and expirations. Hover any cell for full Greeks.

Loading option chain data...

Politician Trades in NVO

Date Politician Party Type Amount Since Buy
Aug 26, 2026 Scott Scott Franklin Purchase $1K-$15K -8.4%
Mar 30, 2026 Alan Armstrong Republican Purchase $15K-$50K +22.5%
Mar 13, 2026 Ro Khanna D Purchase $1K-$15K +13.9%
Feb 13, 2026 Ro Khanna D Purchase $1K-$15K -12.8%
Oct 31, 2025 Lisa C. McClain R Sale $1K-$15K
Oct 30, 2025 Lisa C. McClain R Purchase $1K-$15K -13.6%
Oct 30, 2025 Lisa C. McClain R Sale $1K-$15K
Oct 15, 2025 Marjorie Taylor Greene R Purchase $1K-$15K -23.8%
Oct 15, 2025 Marjorie Taylor Greene R Purchase $1K-$15K -23.8%
Sep 11, 2025 Lisa C. McClain R Purchase $1K-$15K -20.4%

Earnings History

Date Quarter EPS Est. EPS Actual Surprise Result
Aug 05, 2026 Q2 2026 $5.27
Mar 31, 2026 Q1 2026 $5.39 $6.63 +23.1% Beat
Dec 31, 2025 Q4 2025 $5.96 $6.04 +1.4% Beat
Sep 30, 2025 Q3 2025 $4.84 $4.50 -7.0% Miss
Jun 30, 2025 Q2 2025 $6.03 $5.96 -1.1% Miss
Mar 31, 2025 Q4 2025 $5.96 $6.04 +1.4% Beat
Mar 31, 2025 Q1 2025 $6.28 $6.53 +3.9% Beat

Track NVO with ThetaPal

Get insider trade alerts, AI portfolio analysis, and options roll recommendations for NVO and your entire portfolio.